Download Files:

(S)-(+)-Ibuprofen

$35$95

Products Details

Product Description

– (S)-(+)-Ibuprofen ((S)-Ibuprofen), a S(+)-enantiomer of Ibuprofen, is a potent COX-1 and COX-2 inhibitor with IC50s of 2.1 μM and 1.6 μM, respectively. (S)-(+)-Ibuprofen has analgesic, anti-inflammatory, anticancer and antipyretic effects[1][2].

Web ID

– HY-78131A

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– COVID-19-immunoregulation

Molecular Formula

– C13H18O2

References

– [1]N Scheuren, et al. Modulation of transcription factor NF-kappaB by enantiomers of the nonsteroidal drug ibuprofen. Br J Pharmacol. 1998 Feb;123(4):645-52.|[2]Astrid Janssen, et al. Evidence of COX-2 independent induction of apoptosis and cell cycle block in human colon carcinoma cells after S- or R-ibuprofen treatment. Eur J Pharmacol. 2006 Jul 1;540(1-3):24-33.|[3]Evans AM, et al. Comparative pharmacology of S(+)-ibuprofen and (RS)-ibuprofen. Clin Rheumatol. 2001 Nov;20 Suppl 1:S9-14.

CAS Number

– 51146-56-6

Molecular Weight

– 206.28

Compound Purity

– 99.99

SMILES

– OC([C@H](C1=CC=C(CC(C)C)C=C1)C)=O

Clinical Information

– Launched

Research Area

– Inflammation/Immunology

Solubility

– DMSO : 100 mg/mL (ultrasonic)|Ethanol : 100 mg/mL (ultrasonic)|H2O : 1 mg/mL (ultrasonic;warming)

Target

– COX

Isoform

– COX-1;COX-2

Pathway

– Immunology/Inflammation

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.